Analysis of Dose Distribution and Risk of Pneumonitis in Stereotactic Body Radiation Therapy for Centrally Located Lung Tumors: A Comparison of Robotic Radiosurgery, Helical Tomotherapy and Volumetric Modulated Arc Therapy

被引:15
作者
Kannarunimit, Danita [1 ]
Descovich, Martina [2 ]
Garcia, Aaron [2 ]
Chen, Josephine [2 ]
Weinberg, Vivian [2 ]
Mcguinness, Christopher [2 ]
Pinnaduwage, Dilini [2 ]
Murnane, John [2 ]
Gottschalk, Alexander R. [2 ]
Yom, Sue S. [2 ]
机构
[1] King Chulalongkorn Univ Hosp, Dept Radiat Oncol, Bangkok, Thailand
[2] Univ Calif San Francisco, Dept Radiat Oncol, San Francisco, CA 94143 USA
关键词
Central lung; SBRT; Robotic radiosurgery; Helical tomotherapy; VMAT; Pneumonitis; CYBERKNIFE RADIOSURGERY; TRACKING SYSTEM; MEGAVOLTAGE CT; RADIOTHERAPY; CANCER; RECONSTRUCTION; TOXICITY; ACCURACY; SBRT; VMAT;
D O I
10.7785/tcrt.2012.500394
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Stereotactic body radiation therapy (SBRT) to central lung tumors is associated with normal tissue toxicity. Highly conformal technologies may reduce the risk of complications. This study compares physical dose characteristics and anticipated risks of radiation pneumonitis (RP) among three SBRT modalities: robotic radiosurgery (RR), helical tomotherapy (HT) and volumetric modulated arc therapy (VMAT). Nine patients with central lung tumors. 5 cm were compared. RR, HT and VMAT plans were developed per RTOG 0831. Dosimetric comparisons included target coverage, conformity index, heterogeneity index, gradient index, maximal dose at 2 cm from target (D2cm), and dose-volume parameters for organs at risk (OARs). Efficiency endpoints included total beam-on time and monitor units. RP risk was derived from Lyman-Kutcher-Burman modeling on in-house software. The average GTV and PTV were 11.6 +/- 7.86 cm(3) and 36.8 +/- 18.1 cm(3). All techniques resulted in similar target coverage (p = 0.64) and dose conformity (p = 0.88). While RR had sharper fall-off gradient (p = 0.002) and lower D2 cm (p = 0.02), HT and VMAT produced greater homogeneity (p < 0.001) and delivery efficiency (p = 0.001). RP risk predicted from whole or contralateral lung volumes was less than 10%, but was 2-3 times higher using ipsilateral volumes. Using whole (p = 0.04, p = 0.02) or ipsilateral (p = 0.004, p = 0.0008) volumes, RR and VMAT had a lower risk of RP than HT. Using contralateral volumes, RR had the lowest RP risk (p = 0.0002, p = 0.0003 versus HT, VMAT). RR, HT and VMAT were able to provide clinically acceptable plans following the guidelines provided by RTOG 0813. All techniques provided similar coverage and conformity. RR seemed to produce a lower RP risk for a scenario of small PTV-OAR overlap and small PTV. VMAT and HT produced greater homogeneity, potentially desirable for a large PTV-OAR overlap. VMAT probably yields the lowest RP risk for a large PTV. Understanding subtle differences among these technologies may assist in situations where multiple choices of modality are available.
引用
收藏
页码:49 / 60
页数:12
相关论文
共 59 条
[1]  
[Anonymous], 2009, SEAMLESS PHASE 1 2 S
[2]   Dosimetric accuracy of tomotherapy dose calculation in thorax lesions [J].
Ardu, Veronica ;
Broggi, Sara ;
Cattaneo, Giovanni Mauro ;
Mangili, Paola ;
Calandrino, Riccardo .
RADIATION ONCOLOGY, 2011, 6
[3]   A DOSE-VOLUME ANALYSIS OF RADIATION PNEUMONITIS IN NON-SMALL CELL LUNG CANCER PATIENTS TREATED WITH STEREOTACTIC BODY RADIATION THERAPY [J].
Barriger, R. Bryan ;
Forquer, Jeffrey A. ;
Brabham, Jeffrey G. ;
Andolino, David L. ;
Shapiro, Ronald H. ;
Henderson, Mark A. ;
Johnstone, Peter A. S. ;
Fakiris, Achilles J. .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 82 (01) :457-462
[4]   Stereotactic body radiotherapy for medically inoperable patients with stage I non-small cell lung cancer - A first report of toxicity related to COPD/CVD in a non-randomized prospective phase II study [J].
Baumann, Pia ;
Nyman, Jan ;
Hoyer, Morten ;
Gagliardi, Giovanna ;
Lax, Ingmar ;
Wennberg, Berit ;
Drugge, Ninni ;
Ekberg, Lars ;
Friesland, Signe ;
Johansson, Karl-Axel ;
Lund, Jo-Asmund ;
Morhed, Elisabeth ;
Nilsson, Kristina ;
Levin, Nina ;
Paludan, Merete ;
Sederholm, Christer ;
Traberg, Anders ;
Wittgren, Lena ;
Lewensohn, Rolf .
RADIOTHERAPY AND ONCOLOGY, 2008, 88 (03) :359-367
[5]   Image-Guided Robotic Stereotactic Radiation Therapy with Fiducial-Free Tumor Tracking for Lung Cancer [J].
Bibault, Jean-Emmanuel ;
Prevost, Bernard ;
Dansin, Eric ;
Mirabel, Xavier ;
Lacornerie, Thomas ;
Lartigau, Eric .
RADIATION ONCOLOGY, 2012, 7
[6]   RADIATION PNEUMONITIS AFTER HYPOFRACTIONATED RADIOTHERAPY: EVALUATION OF THE LQ(L) MODEL AND DIFFERENT DOSE PARAMETERS [J].
Borst, Gerben R. ;
Ishikawa, Masayori ;
Nijkamp, Jasper ;
Hauptmann, Michael ;
Shirato, Hirk ;
Bengua, Gerard ;
Onimaru, Rikiya ;
Bois, A. de Josien ;
Lebesque, Joos V. ;
Sonke, Jan-Jakob .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 77 (05) :1596-1603
[7]   Radiation pneumonitis in patients treated for malignant pulmonary lesions with hypofractionated radiation therapy [J].
Borst, Gerben R. ;
Ishikawa, Masayori ;
Nijkamp, Jasper ;
Hauptmann, Michael ;
Shirato, Hiroki ;
Onimaru, Rikiya ;
van den Heuvel, Michel M. ;
Belderbos, Jose ;
Lebesque, Joos V. ;
Sonke, Jan-Jakob .
RADIOTHERAPY AND ONCOLOGY, 2009, 91 (03) :307-313
[8]   Application of Robotic Stereotactic Radiotherapy to Peripheral Stage I Non-small Cell Lung Cancer with Curative Intent [J].
Brown, W. T. ;
Wu, X. ;
Fayad, F. ;
Fowler, J. F. ;
Garcia, S. ;
Monterroso, M. I. ;
de la Zerda, A. ;
Schwade, J. G. .
CLINICAL ONCOLOGY, 2009, 21 (08) :623-631
[9]   FITTING OF NORMAL TISSUE TOLERANCE DATA TO AN ANALYTIC-FUNCTION [J].
BURMAN, C ;
KUTCHER, GJ ;
EMAMI, B ;
GOITEIN, M .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1991, 21 (01) :123-135
[10]   CyberKnife with tumor tracking: an effective treatment for high-risk surgical patients with stage I non-small cell lung cancer [J].
Chen, Viola J. ;
Oermann, Eric ;
Vandat, Saloomeh ;
Rabin, Jennifer ;
Suy, Simeng ;
Yu, Xia ;
Collins, Sean P. ;
Subramaniam, Deepa ;
Banovac, Filip ;
Anderson, Eric ;
Collins, Brian T. .
FRONTIERS IN ONCOLOGY, 2012, 2